Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Darunavir/Cobicistat FDC in Healthy Volunteers
NCT05378906Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of darunavir (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration of Darunavir (DRV), Area Under the DRV Concentration-time Curve From Time Zero to Last Quantifiable Time (AUC[0-last]) of DRV and 1 more. Started Jun 2022; status: completed.
02
Drugs
darunavir
Beyond the preview
Go deeper on NCT05378906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378906.